Emulsion-solvent evaporation lines producing long-acting injectable depots from RESOMER LG 855 S begin with an oil phase in which the copolymer is dissolved in dichloromethane at 15–25% w/w; the lactide:glycolide ratio is 85:15 and the inherent viscosity is specified at 0.55 dL/g in chloroform at 25 °C. A dissolved or dispersed active pharmaceutical ingredient is combined with the oil phase under low-shear impeller mixing before the entire oil phase is injected into a continuous aqueous phase containing 1.0–2.5% w/w polyvinyl alcohol with a hydrolysis degree of 85–90%. Emulsion formation in a production-scale rotor-stator device at 4,000–7,000 min⁻¹ for 4–10 min establishes a particle-size distribution that can be shifted from 30 µm to 120 µm by increasing continuous-phase viscosity, reducing shear input, or raising the oil-phase solvent ratio. Solvent removal proceeds by transfer into 2–5% w/w isopropanol in water at 15–20 °C for 3–5 h, followed by hardening, tangential-flow filtration, and lyophilization with an annealing step above −20 °C. Residual dichloromethane is controlled below 600 ppm according to USP 467 and ICH Q3C(R8) Class 2 options; headspace gas chromatography with flame ionization detection is used for release testing. Terminal microspheres are supplied as a dry powder for reconstitution in aqueous injection vehicles, and the final dosage form is evaluated according to ISO 10993-1:2018, ISO 10993-5:2009, and USP 71 sterility requirements. Terminal sterilization by gamma irradiation is generally avoided because chain scission and molecular weight reduction alter release kinetics; ethylene oxide or aseptic filling is preferred when the packaging configuration permits. Storage at −20 °C in sealed, desiccated containers is required because atmospheric moisture accelerates hydrolytic degradation of the copolymer backbone. In-line process controls include oil-phase viscosity at 25 °C, continuous-phase surface tension, and particle-size analysis by laser diffraction each hour of production. Oil-phase viscosity is controlled between 0.1 Pa·s and 1.5 Pa·s by adjusting solvent ratio; higher viscosity shifts the median particle size upward under constant shear. Published data for this specific grade in pilot-scale microsphere lines is limited, so scale-up runs require deliberate adjustment of shear rate, phase ratio, and solvent exchange profile rather than linear amplification of mixing parameters.

Residual solvent control matrix for the emulsion-solvent evaporation route is summarized below.

Hot-Melt Extrusion of Monolithic Rods: Torque, Moisture, and Residence Time Limits

Before hot-melt extrusion of RESOMER LG 855 S into monolithic rods, the material is pre-dried under vacuum at 10 mbar and 25 °C for 48–72 h until residual moisture falls below 0.2%. Barrel set points on a co-rotating twin-screw extruder with 16 mm screw diameter and 40 L/D segmented barrel are normally held between 105 °C and 125 °C, with the die at 115 °C; melt residence times are kept below 120 s because the amorphous copolymer begins to generate lactide monomer and viscosity drift above 130 °C. Screw speeds from 80 min⁻¹ to 150 min⁻¹ are applied, and specific mechanical energy input is monitored to keep drive torque below 70% of the gearbox rating. When the active pharmaceutical ingredient is thermolabile, a downstream side-stuffer is used after the melt seal, and the melt is shaped through a 1.8 mm or 2.0 mm round die before cooling in a 10–15 °C air stream. If 5–10 wt% acetyl tributyl citrate is incorporated as a plasticizer, the barrel profile can be reduced to 100–110 °C, but tensile modulus of the finished rod decreases relative to unplasticized extrudate; published data for this specific grade with plasticizer loadings above 10 wt% is limited. The extruded rods are cut into 2.0–3.5 cm segments, sealed under nitrogen, and tested for melt flow rate according to ISO 1133-1:2022, tensile properties according to ASTM D638-14, and in vitro degradation according to ASTM F1635-16. Biocompatibility evaluation follows ISO 10993-1:2018, ISO 10993-5:2009, and ISO 10993-6:2016. Amine-containing additives and basic active pharmaceutical ingredients must be excluded because they accelerate ester cleavage and destabilize the melt during compounding; moisture levels above 0.5% at feed cause bubble formation, die-pressure fluctuation, and measurable molecular weight loss. The final monolithic rod is suitable for subcutaneous or periodontal implant configurations, but the absence of a crystalline domain means dimensional recovery after cooling must be verified for each die geometry.

What Limits Electrospun Conduit Reproducibility When LG 855 S Is Processed from HFIP?

In electrospinning of RESOMER LG 855 S from 1,1,1,3,3,3-hexafluoro-2-propanol at 8–12% w/v, ambient humidity and solution conductivity control fiber diameter and defect density. Water vapor above 35% RH acts as a non-solvent, producing surface pores and broken fibers before the collector is reached. A solution feed rate of 0.5–1.5 mL/h through a 21–23 G blunt needle, an electrostatic potential of 15–20 kV, and a tip-to-collector distance of 12–18 cm produce fiber diameters between 400 nm and 900 nm, as measured by scanning electron microscopy. A rotating mandrel at 1,500–2,500 min⁻¹ imparts circumferential alignment for tubular scaffolds, while lower rotation speeds produce random deposition appropriate for planar patches. Conductivity is adjusted with 0.05–0.2% w/v tetraethylammonium bromide to suppress bead formation; excessive salt content raises current beyond 20 µA and destabilizes the Taylor cone. Residual solvent is removed by vacuum drying at 30 °C for 24–48 h, and residual levels are characterized by gas chromatography according to ISO 10993-18:2020. Cytotoxicity is assessed per ISO 10993-5:2009, and local tissue response after implantation per ISO 10993-6:2016; for vascular conduit applications, additional evaluation under ISO 7198:2016 is required for burst strength and suture retention. The terminal product is a nonwoven tubular scaffold with a wall thickness from 150 µm to 500 µm, intended for decellularized extracellular matrix reinforcement or peripheral nerve guidance. Incompatibility with residual quaternary ammonium salts must be resolved by ethanol washing because sub-µm fibers retain ionic species in the inter-fiber void volume, and incomplete washing can produce cytotoxic residues even when bulk scaffold viability is acceptable.

When solvent-assisted direct writing is applied to patient-specific osteochondral plugs, RESOMER LG 855 S is dissolved at 20–30 wt% in a 4:1 v/v mixture of dichloromethane and 2,2,2-trifluoroethanol. The solution is loaded into an opaque reservoir and dispensed through a tapered nozzle of 200–400 µm internal diameter under pneumatic pressure of 2–4 bar, while a linear motion stage moves at 8–20 mm/s and layer height is set to 100–200 µm. Rapid solvent evaporation at the nozzle tip increases viscosity and causes intermittent clogging when the ambient dew point exceeds 10 °C or when the working distance is less than 2 mm; a co-axial solvent sheath or a nozzle heater at 30 °C reduces tip solidification. Deposited strands are air-dried for 12–24 h and then vacuum-dried at 25 °C for 24 h to remove residual dichloromethane below 600 ppm, with release testing by headspace gas chromatography under USP 467. The finished scaffold typically exhibits interconnected pores in the 300–600 µm strut-spacing range and porosity of 60–75% when printed with a 0/90° lay-down pattern. Compression testing follows ASTM D695-15 or ISO 844:2014 for rigid cellular polymers after conditioning at 23±2 °C and 50±10% RH. Biological evaluation includes ISO 10993-5:2009 and ISO 10993-6:2016. The process is incompatible with high molecular weight hydrophilic additives that phase-separate from the solvent mixture and block the dispense tip; only solutes that remain in homogeneous solution at 20 °C should be added to the ink. Published data for this specific resin in direct-writing applications is limited, so printability must be confirmed with a series of solvent-ratio and nozzle-diameter trials before scaling beyond 10 cm³ batch volume.

Compression-Moulded Films and Guided Bone Regeneration Barriers

Prior to compression moulding of RESOMER LG 855 S into barrier membranes, the powder is dried to less than 0.2% moisture and pressed between heated platens at 135–155 °C and 5–15 MPa for 30–120 s, with release liners preventing sticking at the lower viscosity limit. The platen gap is controlled to produce films from 200 µm to 500 µm thickness; thickness uniformity is measured by contacting gauge at 9 points per film. Tensile testing according to ASTM D638-14 is used for lot release, and the film is aged in phosphate-buffered saline at 37 °C with pH 7.4 to track mass loss and molecular weight change according to ASTM F1635-16. For 85:15 PLGA, bulk degradation is slower than for 50:50 copolymers; visible fragmentation is typically delayed beyond 12 weeks in vitro, but published data for this specific grade in compression-moulded film geometry is limited. The terminal device is a resorbable guided bone regeneration membrane, with cytotoxicity and implantation evaluation under ISO 10993-5:2009 and ISO 10993-6:2016. Residual stresses from rapid cooling cause warpage, so the film is annealed at 60–70 °C for 2–4 h before packaging. Ethylene oxide sterilization is preferred over gamma irradiation because irradiation at 25 kGy reduces molecular weight and shifts mechanical properties; if gamma sterilization cannot be avoided, post-irradiation tensile testing and degree of degradation mapping are required. The compression-moulded film process is incompatible with fillers that release water at the pressing temperature, because localized hydrolysis creates surface defects and weakens the membrane in the region adjacent to the filler particle.

When Spray-Coated Drug-Eluting Layers Require Slower Hydrolysis than 50:50 PLGA

A drug-eluting coating of this 85:15 PLGA is deposited by ultrasonic spray coating when the layer must survive longer than a 50:50 PLGA under physiological pH and temperature. The copolymer is dissolved in ethyl acetate or acetone at 0.5–3.0% w/v, and an ultrasonic nozzle operating at 60–120 kHz atomizes the solution at a flow rate of 0.05–0.30 mL/min; the substrate is maintained at 35–45 °C to accelerate solvent flash-off and produce a uniform coating of 3–10 µm. Coating thickness is verified by cross-sectional scanning electron microscopy or profilometry at defined locations. The wet film is dried under vacuum at 30 °C for 12–24 h, and residual ethyl acetate or acetone is quantified by USP 467 headspace gas chromatography before terminal packaging. Drug content uniformity is evaluated according to USP 905, hemocompatibility according to ISO 10993-4:2017, and cytotoxicity according to ISO 10993-5:2009. The 85:15 lactide:glycolide ratio reduces the rate of autocatalytic acid generation relative to 50:50 grades, but acidic degradation products still accumulate within thick coatings above 10 µm and can destabilize acid-labile active pharmaceutical ingredients; in such cases, a buffer layer or a thinner coating below 5 µm is required. The coating solution is incompatible with water-miscible additives above 5 vol% because turbidity and phase separation increase surface roughness beyond 1 µm Ra. Substrate geometry with sharp edges produces edge thinning during spray; fixture rotation at 20–60 min⁻¹ is used to improve thickness uniformity. The terminal product is a drug-eluting implant surface or stent coating, but the lower glycolide content requires extended in vivo degradation characterization because animal-model clearance times are longer than those observed with 50:50 PLGA controls.